Hologic, Inc. (Nasdaq:
HOLX), announced today that the U.S. Food and Drug Administration has approved its Cervista HTA system for use with the Company's previously approved Cervista human papillomavirus HR test. The Company's HPV HR test
utilizes Hologic's proprietary Invader technology to detect 14 high risk types of HPV that are associated with cervical cancer and precancerous lesions.
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
